DUBLIN – Novartis AG is broadening its footprint in the cell therapy space by paying $35 million to acquire a 15 percent stake in umbilical cord blood stem cell specialist Gamida Cell Ltd., along with an option to acquire the company outright for another $165 million, plus $435 million more in regulatory, development and commercial milestones.